Living With the Disease HIV/AIDS UPDATE

December 2012
Essence (Time Inc.);Dec2012, Vol. 43 Issue 8, p152
The article provides updates on AIDS disease in the U.S. It mentions the availability of the first rapid in-home HIV test approved by the Food and Drug Administration (FDA) in major retailers including Walmart. It unveils the association of HIV and hepatitis C, creating a double risks for the HIV positive persons. The importance of the implementation of the Affordable Care Act (ACA) on the creation of the Prevention and Public Health Fund is also emphasized.


Related Articles

  • THE DEVIL IS IN THE DETAILS: HEALTH-CARE REFORM, BIOSIMILARS, AND IMPLEMENTATION CHALLENGES FOR THE FOOD AND DRUG ADMINISTRATION. Paradise, Jordan // Jurimetrics: The Journal of Law, Science & Technology;Spring2011, Vol. 51 Issue 3, p279 

    The Biologics Price Competition and Innovation Act (BPCIA), part of the Patient Protection and Affordable Care Act (PPACA), placed a major regulatory challenge in front of the Food and Drug Administration (FDA). The BPCIA grants broad authority to the FDA to develop and implement a market...

  • Biosimilar Milestone. BaƱuelos, Heather D.; Reschovsky, Allison // Contract Pharma;Apr2012, Vol. 14 Issue 3, p18 

    The article focuses on the draft guidance represented by the U.S. Food & Drug Administration in order to assist the pharmaceutical industry in developing biosimilar products. It states that the pathway for licensure of biosimilar products was founded by the Biologics Price Competition and...

  • COMMENT: THE FDA'S MENU LABELING REGULATION: PROMOTING CHANGE THROUGH SHOCK VALUE. Vieder, Rachael // Health Law & Policy;Spring2012, Vol. 6 Issue 1, p15 

    The article comments on the role of the U.S. Food and Drug Administration (FDA) in tackling obesity issues faced by the nation. It also discusses relationship between the FDA and industries affected by the implementation of Section 4205 of the Patient Protection and Affordable Care Act (PPACA)...

  • WEEK IN WASHINGTON.  // BioWorld Insight;5/14/2012, Vol. 20 Issue 20, p6 

    The article offers information on the filing of citizen petition with the U.S. Food and Drug Administration by Abbott Laboratories Inc. which would refer products approved before the U.S Affordable Care Act was signed into law.

  • Biosimilar Development: What is "Highly Similar"? BENTLEY, ELIZABETH // California Journal of Health-System Pharmacy;Jul/Aug2013, Vol. 25 Issue 4, p125 

    The article reports on developments of biosimilars for biologic drugs that are mandated by the Food and Drug Administration (FDA) to become the affordable version of branded drugs with similar requirements for safety, purity and potency. It notes that the European Medicines Agency (EMA) has...

  • Q: Do you support menu labeling for supermarkets? Wootan, Margo; Hatcher, Jennifer // SN: Supermarket News;10/20/2014, Vol. 62 Issue 18, p18 

    The article presents answers to a question on the whether the proposed rule of the U.S. Food and Drug Administration (FDA) on the menu labeling provision under the Affordable Care Act issued on April 2011 should apply also to supermarkets.

  • "Generating the Science Needed for Relevant Communication: How Can Social, Behavioral, and Decision Research Extract the Information that the Public Needs Most from the Wealth of Scientific Knowledge?". Schwartz, Lisa; Woloshin, Steven // AMWA Journal: American Medical Writers Association Journal;2012, Vol. 27 Issue 3, p133 

    The article discusses how social, decision, and behavioral research can get the information needed by the public from scientific knowledge. It highlights three approaches for communicating on prescription drugs, such as commercial communication, public communication, and the drug facts box. It...

  • The US Biosimilars Act Challenges Facing Regulatory Approval. Nick, Cecil // Pharmaceutical Medicine - New Zealand;2012, Vol. 26 Issue 3, p145 

    Ever since the signing of the US healthcare reform legislation, the Patient Protection and Affordable Care Act (PPAC), speculation as to what a US FDA biosimilar programme might look like has been rife. Now the FDA has published guidance documents on biosimilar product development, which has...

  • Insurance Coverage of Contraceptives.  // State Policies in Brief (Series);Feb2014, p1 

    The article reports that health insurance plans are required to cover contraceptive drugs as well as related counseling and services without personal expenses to patients as directed by the U.S. Patient Protection and Affordable Care Act of 2010 (ACA) in the U.S. It indicates that almost all...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics